Ebola Virus Drug Pipeline Advances Through Research by 18+ Global Biopharmaceutical Companies

• INO 4201 — INOVIO Pharmaceuticals: Phase I development.
• Ebola virus vaccine — Auro Vaccines: Phase I development.
• Opaganib — RedHill Biopharma Ltd.: Preclinical development, as reported in the source material.
• RHB-107 — RedHill Biopharma: Preclinical development, as reported in the source material.
• Pan–Ebola — Emergent BioSolutions: Preclinical development.
• ARN 75092 — Arisan Therapeutics: Research-stage candidate.

Other programs identified in the report include a viral vaccine research program and EBV TCR T-cell therapy. Development stages may change as new research findings become available.

Explore candidate-level information through Ebola Virus Clinical Trials.

Key Developments in Ebola Virus Treatment

In May 2024, RedHill Biopharma announced a Chinese patent Notice of Allowance covering opaganib for inhibiting the replication of single-stranded RNA viruses, including Ebola virus, with protection reported through 2035.

In November 2023, SK Bioscience announced a partnership with Hilleman Laboratories Singapore to develop a lower-cost manufacturing process for a second-generation Ebola-Zaire vaccine.

In October 2023, RedHill reported that oral opaganib increased survival time in an Ebola virus animal study conducted by the United States Army Medical Research Institute of Infectious Diseases. The reported findings support further investigation but do not establish clinical efficacy in humans.

Learn more about emerging treatment opportunities through Ebola Virus Drugs : https://www.delveinsight.com/report-store/ebola-virus-competitive-landscape?utm_source=apac&utm_medium=promotion&utm_campaign=akpr 

Scope of the Ebola Virus Pipeline Report

The report provides global coverage of the Ebola virus competitive landscape, including key companies such as Auro Vaccines, INOVIO Pharmaceuticals, RedHill Biopharma Ltd., Emergent BioSolutions, Arisan Therapeutics, TFF Pharmaceuticals, and China Immunotech. Featured therapies include the Ebola virus vaccine, INO 4201, opaganib, RHB-107, Pan–Ebola, ARN 75092, and other research programs.

Conclusion

The Ebola virus drug development landscape reflects sustained efforts to strengthen outbreak preparedness through vaccines, antibody therapies, antiviral candidates, and improved manufacturing strategies. More than 18 companies and over 20 pipeline candidates identified in DelveInsight’s report illustrate the breadth of research underway. Nevertheless, clinical development risks, unpredictable outbreaks, and distribution challenges remain significant barriers. Continued collaboration among biopharmaceutical companies, governments, research institutions, and global health organizations will be important for advancing promising candidates. DelveInsight’s competitive landscape report offers insights into pipeline programs, company activity, treatment developments, and potential opportunities shaping the future of Ebola virus prevention and care.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Abhishek kumar

info@delveinsight.com